Scholars Central

EditorialPublished 22 Dec 2011

Finally, A Routine Use for ES and iPS Cells

Authors: David T. Harris

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

For more than a decade now the scientific community has been waiting for embryonic stem (ES) and induced pluripotent stem (iPS) cells to mature from an interesting research observation to a useful clinical tool. Unfortunately, it has become readily apparent that there are many barriers to clinical implementation for both ES and iPS cells. Allogenicity and the threat of immune rejection by the host, the risk of teratogenicity and development of tumors in anatomical locations that would be life-threatening (e.g., the brain), and the time and cost involved to derive differentiated tissues for clinical use (estimated to be 6 months or more and in excess of $50,000 per tissue) have thwarted the rapid transition of these cells from the bench to the bedside. Although the use of iPS cells can alleviate the concern of immune rejection found with ES cells, it does not remove the other problems and reports of extensive genomic instability only serve to further limit this technology from clinical use. These issues have put this field under intense scrutiny which has increased costs as well as federal regulatory oversight. In fact, these difficulties have resulted in one of the major players in this field, Geron, to withdraw from these endeavors. It is doubtful that either ES or iPS cells would ever be given directly to patients, and it is very difficult to conceive of even bringing tissues and cells derived from either source to fruition for patient benefit (although some companies are trying).

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioengineering and Bioelectronics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioengineering and Bioelectronics
  • SubjectBiochemistry & Biotechnology
  • BylineArticles whose byline prints “David T. Harris”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels